A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. [PDF]
Lessons learnedThe combination of standard dose abiraterone acetate and BEZ235, a pan-class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC.Although the clinical development of BEZ235 has been discontinued in prostate ...
Friedlander, Terence+6 more
core +1 more source
Research progress on animal models of oral mucositis caused by radiotherapy and chemotherapy
Inflammation of the oral mucosa induced by radiotherapy and/or chemotherapy may cause pain, difficulty speaking and swallowing, an increased risk of local and systemic infections, and even interrupt cancer treatment, which can seriously affect a patient ...
ZOU Xiaolong+3 more
doaj +1 more source
Management of oral mucositis [PDF]
Oral mucositis is one of the most common oral complications of cancer treatment. Studies have shown some interventions that reduce the severity of this condition, but there is not a specific treatment proved that really prevents or treats mucositis ...
da Mota Vasconcelos Brasil Catarina+3 more
doaj +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S.+17 more
core +5 more sources
Mucosal dendritic cells shape mucosal immunity [PDF]
Dendritic cells (DCs) are key modulators that shape the immune system. In mucosal tissues, DCs act as surveillance systems to sense infection and also function as professional antigen-presenting cells that stimulate the differentiation of naive T and B cells.
Mi-Na Kweon+2 more
openaire +3 more sources
Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma [PDF]
PURPOSE: To assess the safety of the superoxide dismutase mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal cancer (OCC) and to assess the potential of GC4419 to reduce severe oral ...
Adkins, Douglas+13 more
core +2 more sources
Oral mucositis is one of the most common complications of cancer therapy. It is a nonhematologic complication of cytotoxic chemotherapy and radiotherapy and reduces the quality of life. It is estimated that 40% the cases on standard chemotherapy may develop oral mucositis.
Singh, Vibha, Singh, Akhilesh Kumar
openaire +3 more sources
Mukositis Oral dan Kualitas Hidup Spesifik–Mukositis Oral pada Anak Kanker yang Menjalani Kemoterapi
One of the side effects generally occur during chemotherapy is oral mucositis. Disorders due to oral mucositis often affects the psychological and decreased quality of life of children.
Dwi Novrianda, Yulastri Arif
doaj +1 more source
Systematic Review of Laser and Other Light Therapy for the Management of Oral Mucositis in Cancer Patients [PDF]
Background The aim of this study was to review the available literature and define clinical practice guidelines for the use of laser and other light therapies for the prevention and treatment of oral mucositis.
Brian Hodgson+10 more
core +2 more sources
Oral platelet gel supernatant plus supportive medical treatment versus supportive medical treatment in the management of radiation-induced oral mucositis: a matched explorative active control trial by propensity analysis [PDF]
OBJECTIVES:: In this active control trial, the rate of radio-induced WHO grade 3/4 oral mucositis and the change in quality of life, assessed by OMWQ-HN, were measured in subjects with head and neck cancer treated by platelet gel supernatant (PGS) and ...
Bonfili P+15 more
core +1 more source